Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05296889

Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical

Multicenter Post market clinical follow-up Study on the Safety and Performance of Ennovate® Cervical - Prospective, pure data collection of all Ennovate Cervical patients in Total Indications

Recruiting

Interested in participating?

Request Info

Key information

About this study

This clinical study is one of the Post market clinical follow-up measures that enables the manufacturer to monitor the clinical safety and performance of the Ennovate® Cervical system. The study enables a quick, but detailed implant documentation, which is of great interest for the current and future users of the internal fixation system targeted in this study. It includes the relevant outcomes to evaluate safety and efficacy of the implant system for various indications in trauma and degenerative disorders.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is minimum 18 years old
  • Informed Consent in the documentation of clinical and radiological results
  • Patient has indication according to Instructions for Use (IFU)
  • Patient is not pregnant

Exclusion criteria

  • Patient's clear unability or unwillingness to participate in follow-up examinations

Treatment and study plan

posterior stabilization for the cervical spine

Device

The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.

Primary outcomes

  1. Change of Pain

    Time frame: preoperatively, at 3 months postoperatively and at 12 months postoperatively

    Pain will be assessed by the patient using the Visual Analogue Scale (VAS) which states "0" at one end representing "no pain" and "100" at the opposite end representing "maximal/worst pain".

Secondary outcomes

  1. Change of Quality of life

    Time frame: preoperatively, at 3 months postoperatively and at 12 months postoperatively

    In order to analyze the quality of life of the patients, the 5-dimension 5-level score of EuroQol Group (EQ-5D-5L) is used. The score is self-completed by the patient. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

  2. Change of Neurological status

    Time frame: preoperatively, at 3 months postoperatively and at 12 months postoperatively

    The Japanese Orthopaedic Association (JOA) myelopathy score is a disease-specific and physician oriented system that mainly assesses the neurological status of the patient and enables surgeons to compare the changes in the neurological status of the patient before and after certain treatments. However, the JOA score does not include patients' satisfaction, disability, handicaps, or general health (physical and mental health), which can be affected by cervical myelopathy.

  3. Change of Disability

    Time frame: preoperatively, at 3 months postoperatively and at 12 months postoperatively

    The Neck Disability Index (NDI) is designed to measure neck-specific disability. The questionnaire has 10 items to measure patient-reported disability secondary to neck pain and activities of daily living including personal care, lifting, reading, headaches, concentration, work status, driving, sleeping and recreation and patients rate their status from 0 (best) to 5 (worst imaginable). Individual item responses are summed to a total score, where 0 points indicate no activity limitations and 50 points indicate complete activity limitation.

  4. Bone fusion

    Time frame: at final follow-up 12 months postoperatively

    After cervical stabilization fusion of the treated segment is aspired in most cases. The fusion status can be determined from radiographs (static or dynamic). Bony fusion can be characterized quantitatively by the fusion rate.

  5. Cumulative number of side effects

    Time frame: throughout the follow-up up to 12 months postoperatively

    Occurrence of complications potentially associated with the implanted devices can never be fully excluded during spinal surgery. In order to monitor potential complication and to identify so far unknown complications Adverse Events and Serious Adverse Events deemed related to the investigational device are recorded.

Study contacts

Contact information is provided by the study sponsor or research team.

Sarah Mattes

CONTACT

[email protected]

+497461950

Stefan Maenz, Dr.

CONTACT

[email protected]

+497461950

Sponsors and collaborators

Lead sponsor

Aesculap AG

Industry

Collaborators

  • Raylytic GmbH

Registry information

Official study title

Multicenter Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical - a Prospective Study on Total Indications

Acronym: CERISE

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Mar 25, 2022
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.